Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 2;16(7):1279–1295. doi: 10.1080/15548627.2019.1668606

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Informa UK Limited, trading as Taylor & Francis Group

PMC Copyright notice

Figure 6. — The MAPK1/3-RPS6KA pathway is activated through DRD3 and DRD2 maintaining RPS6 phosphoryation in PPX treated cells. (A-F) Western blot for total and phosphorylated forms of MAPK1/3 at Thr202/Tyr204 (p-MAPK1/3), RPS6KA at Ser380 (p-RPS6KA), and RPS6 at Ser235/236 (p-RPS6) in mice (A and D), DRD3- (B and E) and DRD2-HEK cells (C and F). MAPK1/3-RPS6KA signaling is acutely activated by PPX in WT mice and in DRD3- and DRD2-HEK cells, and the activity is maintained after prolonged treatment. (G and H) Western blot for RPS6 and its phosphorylated form at Ser235/236 in DRD3-HEK cells treated with either PPX, the MAPK1/3 inhibitor PD98059 or both (PD98059-PPX). RPS6 phosphorylation was impaired in PPX cells only when MAPK1/3 was inhibited.